South Africa Central Nervous System Therapeutic Market to Reach US$ 3,686.91 Mn at a CAGR of 5.6% in 2027 | The Insight Partners

South Africa Central Nervous System (CNS) Therapeutic Market to 2027 - Regional Analysis and Forecasts by Disease Type (Neurovascular Diseases, Degenerative Disorders, Mental Health, Trauma, Others); Drug Type (Analgesics, Nervous System Drugs, Anesthetics, Anti-Parkinson Drugs, Anti-Epileptics, Others); Distribution Channel (Hospital Pharmacies, Retail Pharmacies) and Geography

Publication Month: Sep 2019 | Report Code: TIPRE00006580 | No. of Pages: 76 | Category: Pharmaceuticals | Status: Published

The South Africa Central Nervous System (CNS) Therapeutic market is expected to reach US$ 3,686.91 Mn in 2027 from US$ 2,267.59 Mn in 2018. The market is estimated to grow with a CAGR of 5.6% from 2019-2027 from 2019-2027.

 

Rising prevalence of CNS diseases such as malnutrition, malaria, the human immunodeficiency virus & the acquired immune deficiency syndrome (HIV/AIDS), and demographic transitions are expected to surge the market growth. However, high cost of treatment is likely to have a negative impact on the growth of the market in the coming years.

 

Neurological disorders are very prevalent in Sub-Saharan Africa. The factors responsible for the growing burden include difficult perinatal situations, malnutrition, malaria, the human immunodeficiency virus & the acquired immune deficiency syndrome (HIV/AIDS), and demographic transitions. The primary neurological disorders include mental retardation, cerebral palsy, developmental disorders, epilepsy, peripheral neuropathy, stroke, trauma, and alcohol abuse. According to South African Pharmaceutical Journal in 2016, an estimated 818, 106 people are getting dementia per year, presently affecting more than 4 million people. The number is anticipated to be more than 14 million by 2050. Furthermore, HIV-associated dementia (HAD) is dominant in 15–30% of untreated adults with late-stage disease. The elderly patients, who previously have an increased risk of non-AIDS related dementias, are more prone to untreated HIV. Such a rising prevalence of CNS disorders is expected to create a demand for the central nervous system (CNS) therapeutic across the world.

 

South Africa Central Nervous System (CNS) Therapeutic market, based on drug type was segmented into analgesics, nervous system drugs, anesthetics, anti-parkinson drugs, anti-epileptics, others. In 2018, the analgesics segment held the largest share of the market, by drug type. This segment is also anticipated to grow at the highest rate during the forecast period because they are used to relive pain which provides relief to patients without being consciousness.


Exhibit: South Africa Drug Type Market Revenue and Forecasts to 2027 (US$ Mn)


 

South Africa Central Nervous System (CNS) Therapeutic – MARKET SEGMENTATION

By Disease Type

  • Neurovascular Diseases
  • Degenerative Disorders
  • Mental Health
  • Trauma
  • Others

By Drug Type

  • analgesics
  • Nervous System Drugs
  • Anesthetics
  • Anti-Parkinson Drugs
  • Anti-Epileptics
  • Others

By Distribution Channel

  • Hospitals Pharmacies
  • Retail Pharmacies

 

Companies Mentioned

  • Eli Lilly and company
  • Pfizer Inc.
  • Merck & Co., Inc.
  • AstraZeneca
  • Novartis AG
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Lundbeck
  • Adcock Ingram
  • Lupin Limited

 

1.             Introduction

1.1       Scope of the Study

1.2       The Insight Partners Research Report Guidance

1.3       Market Segmentation

2.             South Africa Central Nervous System (CNS) Therapeutic Market – Key Takeaways

3.             Research Methodology

3.1       Coverage

3.2       Secondary Research

3.3       Primary Research

4.             South Africa Central Nervous System (CNS) Therapeutic Market – Market Landscape

4.1       Overview

4.2       PEST Analysis

4.2.1        South Africa PEST Analysis

4.3       Expert Opinions

5.             Central Nervous System (CNS) Therapeutic Market – Key Industry Dynamics

5.1       Key Market Drivers

5.1.1        Rising Prevalence of CNS Disorders

5.2       Key Market Restraints

5.2.1        High Cost of Treatment

5.3       Key Market Opportunities

5.3.1        Increase in Geriatric Population And Associated Diseases

5.4       Future Trends

5.4.1        Increasing Wearable Devices for Central Nervous System (CNS)

5.5       Impact Analysis

6.             South Africa Central Nervous System (CNS) Therapeutic Market – South Africa Market Analysis

6.1       Overview

6.2       South Africa Central Nervous System (CNS) Therapeutic Market – Revenue Forecasts and Analysis –  2018- 2027

7.             South Africa Central Nervous System (CNS) Therapeutic Market Analysis– by Disease Type

7.1       Overview

7.2       South Africa Central Nervous System (CNS) Therapeutic Market, By Disease Type 2018 & 2027 (%)

7.3       Neurovascular Diseases Market

7.3.1        Overview

7.3.2        South Africa Neurovascular Diseases Market Revenue and Forecasts to 2027 (US$ Mn)

7.4       Degenerative Disorders Market

7.4.1        Overview

7.4.2        South Africa Degenerative Disorders Market Revenue and Forecasts to 2027 (US$ Mn)

7.5       Mental Health Market

7.5.1        Overview

7.5.2        South Africa Mental Health Market Revenue and Forecasts to 2027 (US$ Mn)

7.6       Trauma Market

7.6.1        Overview

7.6.2        South Africa Trauma Market Revenue and Forecasts to 2027 (US$ Mn)

7.7       Others Market

7.7.1        Overview

7.7.2        South Africa Others Market Revenue and Forecasts to 2027 (US$ Mn)

8.             South Africa Central Nervous System (CNS) Therapeutic Market Analysis– by Drug Type

8.1       Overview

8.2       South Africa Central Nervous System (CNS) Therapeutic Market, By Drug Type 2018 & 2027 (%)

8.3       Analgesics Market

8.3.1        Overview

8.3.2        South Africa Analgesics Market Revenue and Forecasts to 2027 (US$ Mn)

8.4       Anesthetics Market

8.4.1        Overview

8.4.2        South Africa Anesthetics Market Revenue and Forecasts to 2027 (US$ Mn)

8.5       Anti-Parkinson Drugs Market

8.5.1        Overview

8.5.2        South Africa Anti-Parkinson Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

8.6       Anti-Epileptics Drugs Market

8.6.1        Overview

8.6.2        South Africa Anti-Epileptics Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

8.7       Others Drugs Market

8.7.1        Overview

8.7.2        South Africa Others Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

9.             South Africa Central Nervous System (CNS) Therapeutic Market Analysis– by Distribution Channel

9.1.1        Overview

9.1.2        South Africa Central Nervous System (CNS) Therapeutic Market, By Distribution Channel  2018 & 2027 (%)

9.1.3        Hospital Pharmacies Market

9.1.4        Overview

9.1.5        South Africa Hospital Pharmacies Market Revenue and Forecasts to 2027 (US$ Mn)

9.1.6        Retail Pharmacies Market

9.1.6.1      Overview

9.1.6.2      South Africa Retail Pharmacies Market Revenue and Forecasts to 2027 (US$ Mn)

10.          Central Nervous System (CNS) Therapeutic Market – Industry Landscape

10.1    Overview

10.2    Growth Strategies done by the companies in the Market, (%)

10.3    Organic Developments

10.3.1     Overview

10.4    Inorganic developments

10.4.1     Overview

11.          Central Nervous System (CNS) Therapeutic Market–Key Company Profiles

11.1    Eli Lilly and company

11.1.1     Key Facts

11.1.2     Business Description

11.1.3     Financial Overview

11.1.4     Product Portfolio

11.1.5     SWOT Analysis

11.1.6     Key Developments

11.2    Pfizer Inc.

11.2.1     Key Facts

11.2.2     Business Description

11.2.3     Financial Overview

11.2.4     Product Portfolio

11.2.5     SWOT Analysis

11.2.6     Key Developments

11.3    Merck & Co., Inc.

11.3.1     Key Facts

11.3.2     Business Description

11.3.3     Financial Overview

11.3.4     Product Portfolio

11.3.5     SWOT Analysis

11.3.6     Key Developments

11.4    AstraZeneca

11.4.1     Key Facts

11.4.2     Business Description

11.4.3     Financial Overview

11.4.4     Product Portfolio

11.4.5     SWOT Analysis

11.4.6     Key Developments

11.5    Novartis AG

11.5.1     Key Facts

11.5.2     Business Description

11.5.3     Financial Information

11.5.4     Product Portfolio

11.5.5     SWOT Analysis

11.5.6     Key Developments

11.6    Takeda Pharmaceutical Company Limited

11.6.1     Key Facts

11.6.2     Business Description

11.6.3     Financial Information

11.6.4     Product Pipeline

11.6.5     SWOT Analysis

11.6.6     Key Developments

11.7    Teva Pharmaceutical Industries Ltd.

11.7.1     Key Facts

11.7.2     Business Description

11.7.3     Financial Overview

11.7.4     Product Portfolio

11.7.5     SWOT Analysis

11.7.6     Key Developments

11.8    Lundbeck

11.8.1     Key Facts

11.8.2     Business Description

11.8.3     Financial Overview

11.8.4     Product Portfolio

11.8.5     SWOT Analysis

11.8.6     Key Developments

11.9    Adcock Ingram

11.9.1     Key Facts

11.9.2     Business Description

11.9.3     Financial Overview

11.9.4     Product Portfolio

11.9.5     SWOT Analysis

11.9.6     Key Developments

11.10 Lupin Limited

11.10.1   Key Facts

11.10.2   Business Description

11.10.3   Financial Information

11.10.4   Product Portfolio

11.10.5   SWOT Analysis

11.10.6   Key Developments

12.          Appendix

12.1    About The Insight Partners

12.2    Glossary of Terms

LIST OF TABLES

Table 1.             Organic Developments Done By Companies

Table 2.             Inorganic developments done by Companies

Table 3.             Glossary of Terms, Central Nervous System (CNS) Therapeutic Market

 

LIST OF FIGURES

Figure 1.           Central Nervous System (CNS) Therapeutic Market Segmentation

Figure 2.           South Africa Central Nervous System (CNS) Therapeutic Market Overview

Figure 3.           Mental Health Disease Segment Held Largest Share Of The Disease Type Segment In Central Nervous System (CNS) Therapeutic Market

Figure 4.           South Africa Nervous System (CNS) Therapeutic Market, Industry Landscape

Figure 5.           South Africa: PEST Analysis

Figure 6.           Impact Analysis of Driver and Restraints Pertaining to Central Nervous System (CNS) Therapeutic Market

Figure 7.           South Africa Central Nervous System (CNS) Therapeutic Market – Revenue Forecasts and Analysis –  2018- 2027

Figure 8.           South Africa Central Nervous System (CNS) Therapeutic Market, by Disease Type 2018 & 2027 (%)

Figure 9.           South Africa Neurovascular Diseases Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 10.        South Africa Degenerative Disorders Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 11.        South Africa Mental Health Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 12.        South Africa Trauma Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 13.        South Africa Others Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 14.        South Africa Central Nervous System (CNS) Therapeutic Market, by Drug Type 2018 & 2027 (%)

Figure 15.        South Africa Analgesics Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 16.        South Africa Anesthetics Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 17.        South Africa Anti-Parkinson Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 18.        South Africa Anti-Epileptics Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 19.        South Africa Others Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 20.        South Africa Central Nervous System (CNS) Therapeutic Market, by Distribution Channel 2018 & 2027 (%)

Figure 21.        South Africa Hospital Pharmacies Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 22.        South Africa Retail Pharmacies Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 23.        Growth Strategies done by the companies in the Market, (%)

 

The List of Companies

 

  1. Eli Lilly and company
  2. Pfizer Inc.
  3. Merck & Co., Inc.
  4. AstraZeneca
  5. Novartis AG
  6. Takeda Pharmaceutical Company Limited
  7. Teva Pharmaceutical Industries Ltd.
  8. Lundbeck
  9. Adcock Ingram
  10. Lupin Limited